Enrique Feoli, MD
Neurology · Bangor, MENPI 1629097852
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,111 and has fallen 72.4% since, to $306 in 2025.
Across 274 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$878
- UCB, Inc.$608
- SK Life Science, Inc.$457
- Greenwich Biosciences, Inc.$440
- Eisai Inc.$374
- Sunovion Pharmaceuticals Inc.$285
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,842100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 12 | $878 |
| UCB, Inc. | 37 | $608 |
| SK Life Science, Inc. | 31 | $457 |
| Greenwich Biosciences, Inc. | 31 | $440 |
| Eisai Inc. | 17 | $374 |
| Sunovion Pharmaceuticals Inc. | 21 | $285 |
| Jazz Pharmaceuticals Inc. | 40 | $270 |
| Neurelis, Inc. | 18 | $266 |
| Novartis | 11 | $176 |
| Livanova USA, Inc. | 10 | $174 |
| Sumitomo Pharma America, Inc. | 7 | $121 |
| Biocodex, Inc. | 4 | $113 |
| Supernus Pharmaceuticals, Inc. | 6 | $82 |
| Medtronic | 1 | $79 |
| Aquestive Therapeutics, Inc. | 4 | $76 |
| Aucta Pharmaceuticals, Inc. | 5 | $66 |
| Mallinckrodt Enterprises LLC | 4 | $64 |
| Pyros Pharmaceuticals, Inc. | 1 | $58 |
| Zimmer Biomet | 1 | $57 |
| Aprecia Pharmaceuticals, LLC | 4 | $55 |
| Catalyst Pharmaceuticals, Inc. | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Nobelpharma America, LLC | 1 | $25 |
| Otter Pharmaceuticals, LLC | 1 | $17 |
| AbbVie | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$449
- Fycompa$125
- RNS System$113
How this compares
$4,859 in reported general payments places this provider in the 80th percentile of 69 neurology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 46 | $79,744 |
| AptiomEslicarbazepine Acetate | 33 | $69,935 |
| EpidiolexCannabidiol (Cbd) | 17 | $58,544 |
| KeppraLevetiracetam | 24 | $47,581 |
| XcopriCenobamate | 33 | $41,561 |
| Keppra XrLevetiracetam | 13 | $41,014 |
| VimpatLacosamide | 23 | $31,436 |
| OnfiClobazam | 17 | $26,690 |
| LamictalLamotrigine | 13 | $19,018 |
| TrileptalOxcarbazepine | 22 | $15,126 |
| Oxcarbazepine | 92 | $12,268 |
| Lacosamide | 136 | $11,544 |
| Oxtellar XrOxcarbazepine | 18 | $10,236 |
| Levetiracetam | 249 | $8,894 |
| Tegretol XrCarbamazepine | 23 | $7,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat | $608 | $111,17969 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $285 | $69,93533 claims |
| SK Life Science, Inc.Xcopri | $457 | $41,56133 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $82 | $10,23618 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $77946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 neurology providers in Maine.
Other neurology in Bangor
- Carrie DowneyBangor$6K
- Mirna HajjarBangor$918
- Markos PoulopoulosBangor$693
- Bakhtier NurmukhamedovBangor$462
- Aileen Cangiano-HeathBangor$255
- Tarek WazzanBangor$201
- Suzanne BourqueBangor$189
- Ch Hassan AliBangor$133
- Karl SanzenbacherBangor$87
- Sally KirkpatrickBangor$26
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.